

# Pathogenesis of *Streptococcus pneumoniae*



**Lauren Joy M<sup>c</sup>Allister, BSc (Mol. Biol.), BSc (Hons)**

A thesis submitted in fulfillment of the requirements for the degree of  
Doctor of Philosophy from the University of Adelaide

May, 2010

Research Centre for Infectious Diseases,  
School of Molecular & Biomedical Sciences,  
University of Adelaide,  
Adelaide, S.A., Australia

**This thesis is dedicated to my mother, and sisters Janine and  
Suzanne.**

---

## Table of Contents

---

<b>Abstract</b> .....	<b>x</b>
<b>Declaration</b> .....	<b>xiii</b>
<b>Acknowledgements</b> .....	<b>xiv</b>
<b>List of Abbreviations</b> .....	<b>xvii</b>

---

### Chapter 1: General Introduction

---

<b>1.1 Historical Background</b> .....	<b>1</b>
<b>1.2 Pneumococcal Disease</b> .....	<b>3</b>
<b>1.3 Pneumococcal Virulence</b> .....	<b>6</b>
1.3.1 The pneumococcal capsule .....	8
1.3.2 Serotype, sequence type and genome .....	9
1.3.3 Virulence proteins .....	16
1.3.3.1 Pneumococcal surface protein A (PspA) .....	16
1.3.3.2 Pneumococcal surface protein C (PspC) .....	16
1.3.3.3 Neuraminidase A (NanA) .....	17
1.3.3.4 Pneumolysin (Ply) .....	18
1.3.3.4 Autolysin (LytA) .....	18
1.3.4 Phase variation .....	19

1.3.5 Physiological states .....	21
<b>1.4 Otitis Media .....</b>	<b>24</b>
1.4.1 OM pathogenesis .....	25
1.4.3 OM in Australian Aboriginal children .....	26
1.4.4 Control of OM: current and future strategies .....	28
1.4.5 OM and the pneumococcus .....	31
1.4.5.1 Serotype and genotype .....	31
1.4.5.2 OM-associated proteins .....	32
1.4.5.3 Phase variation in OM .....	33
1.4.5.4 Biofilms in OM .....	34
<b>1.5 Aims of the Project .....</b>	<b>35</b>

---

## **Chapter 2: Materials and Methods**

---

<b>2.1 General Chemicals and Reagents .....</b>	<b>37</b>
2.1.1 Antibiotics .....	37
<b>2.2 Bacterial Strains and Growth .....</b>	<b>38</b>
2.2.1 <i>S.pneumoniae</i> Strains .....	38
2.2.2 Pneumococcal Growth and Storage .....	41
2.2.3 Optochin sensitivity .....	41
2.2.4 Quellung Reaction .....	42
2.2.5 Determination of colony opacity phenotype .....	42
2.2.6 Uronic acid assay .....	42
2.2.7 Determination of growth curves .....	43
2.2.8 Purple broth assay .....	44

2.2.9 Biofilm assay	44
2.2.10 Passaging of pneumococcal strains	45
2.2.11 <i>E.coli</i> strains, growth and storage	45
<b>2.3 Oligonucleotide Primers</b>	<b>46</b>
2.3.2 Oligonucleotide Adaptors	53
<b>2.4 Protein Analysis</b>	<b>54</b>
2.4.1 Preparation of whole cell lysates	54
2.4.2 SDS-PAGE	54
2.4.3 Western Blot Analysis	54
2.4.4 Haemolysis Assay	55
<b>2.5 DNA Isolation and Manipulation</b>	<b>56</b>
2.5.1 Agarose Gel Electrophoresis	56
2.5.2 Pneumococcal chromosomal DNA isolation	57
2.5.3 Pneumococcal chromosomal DNA isolation using phenol	57
2.5.4 Restriction endonuclease digestion of DNA	58
2.5.5 Polymerase chain reaction (PCR)	58
2.5.6 Purification of PCR products and Restriction Digests	59
2.5.7 Cloning of PCR product	59
2.5.8 Plasmid Miniprep	60
2.5.9 DNA sequencing	60
2.5.10 Next generation sequencing	61
2.5.11 Bioinformatics	61
<b>2.6 Multi Locus Sequence Typing</b>	<b>62</b>
<b>2.7 DNA Microarray</b>	<b>62</b>
<b>2.8 PCR-Based Subtraction Hybridisation</b>	<b>63</b>

<b>2.9 Southern Hybridisation</b> .....	<b>64</b>
2.9.1 Preparation of membrane .....	64
2.9.2 Hybridisation .....	64
2.9.3 Generation of probes .....	65
2.9.4 Development of the Membrane .....	65
<b>2.10 RNA Isolation and Manipulation</b> .....	<b>65</b>
2.10.1 Hot-Phenol RNA Extraction .....	65
2.10.2 Reverse Transcription-PCR (RT-PCR) .....	67
2.10.3 Real-time RT-PCR .....	67
<b>2.11 Pneumococcal Transformation</b> .....	<b>68</b>
2.11.1 Preparation of competent cells (CTM method) .....	68
2.11.2 Transformation using CTM .....	68
2.11.3 Transformation using THY .....	69
2.11.4 Transformation using THY supplemented with HCl and glycine .....	69
2.11.5 Transformation using THY supplemented with antibiotics .....	70
2.11.5. 1 Supplementation with streptomycin .....	70
2.11.5. 2 Supplementation with mitomycin C .....	70
<b>2.12 In Vivo Pathogenesis Studies</b> .....	<b>71</b>
2.12.1 Intraperitoneal and pneumonia/sepsis studies .....	71
2.12.2 Intraperitoneal competition .....	72
2.12.3 Intranasal colonisation study .....	73
2.12.4 Intranasal competition .....	74
2.12.5 Pneumonia/Sepsis Competition .....	75

---

## **Chapter 3: Initial Characterisation of Serotype 3 and Serogroup 11 Clinical Isolates**

---

<b>3.1 Introduction</b> .....	<b>76</b>
<b>3.2 Initial Characterisation of Isolates</b> .....	<b>79</b>
3.2.1 Western blot analysis, PCR and sequencing of selected pneumococcal virulence factors .....	79
3.2.1.1 Western blot and sequence analysis of serotype 3 strains .....	79
3.2.1.2 Western blot and sequencing analysis of serogroup 11 strains .....	83
3.2.1.3 PCR analysis of <i>nanB</i> and <i>nanC</i> in selected serotype 3 and serogroup 11 strains .....	87
3.2.2 Haemolysis assay .....	89
3.2.3 MLST typing .....	90
3.2.4 Uronic acid assay .....	93
3.2.5 Animal studies .....	94
3.2.5.1 Virulence models .....	96
3.2.5.2 Colonisation model .....	99
<b>3.3 Capsule Switch Study</b> .....	<b>103</b>
3.3.1 Creation of a capsule switch mutant .....	106
3.3.2 Growth curve of the capsule switch variant .....	107
3.3.3 Pneumonia sepsis model .....	107
<b>3.4 Discussion</b> .....	<b>112</b>
3.4.1 Protein analysis and MLST .....	112
3.4.2 Virulence and colonisation studies .....	116
3.4.3 Influence of serotype on virulence .....	118

---

## **Chapter 4: DNA Microarray Analysis and PCR-based Subtractive Hybridisation**

---

<b>4.1 Introduction</b> .....	<b>121</b>
<b>4.2 DNA Microarray Analysis</b> .....	<b>122</b>
4.2.1 Genomic comparison of representative serotype 3 isolates of ST180 and ST458 .....	123
4.2.2 Genomic comparison of highly related serotype 3 isolates .....	127
4.2.3 Genomic comparison of serogroup 11 pneumococcal isolates .....	128
4.2.4 Genomic comparison of serotype 3 and serogroup 11 isolates .....	133
<b>4.3 PCR-based Subtractive Hybridisation</b> .....	<b>136</b>
4.3.1 Genomic DNA .....	140
4.3.2 Adaptor ligation .....	140
4.3.3 Hybridisations and nested PCR .....	142
4.3.4 Subtractive hybridisation efficiency .....	144
4.3.5 Reduction of subtractive hybridisation background .....	146
4.3.6 Sequencing .....	149
<b>4.4 Discussion</b> .....	<b>150</b>

---

## **Chapter 5: Identification of a Genomic Island Carrying a Putative Cellobiose PTS**

---

<b>5.1 Introduction</b> .....	<b>156</b>
<b>5.2 Results</b> .....	<b>157</b>
5.2.1 PCR analysis of the distribution of PTS 1 and PTS 2 .....	157
5.2.2 Bioinformatic analysis of the distribution of putative cellobiose PTSs .....	160
5.2.3 Isolation of a genomic island carrying PTS 1 .....	163



---

5.2.4 Distribution of the sulfatase in the tester strains .....	169
5.2.5 General distribution of the sulfatase .....	170
5.2.6 <i>RsaI</i> restriction sites of the island .....	170
5.2.7 Expression of the putative cellobiose PTS and sulfatase .....	171
<b>5.3 Discussion .....</b>	<b>174</b>
5.3.1 Potential role of the proteins identified in the genomic island .....	175

---

## **Chapter 6: Mutational Analysis of the PTS 1 Genomic Island**

---

<b>6.1 Introduction .....</b>	<b>178</b>
<b>6.2 Mutational Analysis of the Whole Genomic Island .....</b>	<b>179</b>
6.2.1 Construction of mutants in WCH206 and MSHR5 .....	179
6.2.2 Attempts to mutate MSHR17 .....	179
6.2.3 Cellobiose fermentation .....	181
6.2.4 Growth .....	185
6.2.5 Effect of mutation on biofilm formation .....	185
6.2.6 Virulence studies .....	191
6.2.6.1 Intraperitoneal virulence .....	191
6.2.6.2 Intraperitoneal competition study .....	191
6.2.6.3 Pneumonia/sepsis model .....	193
6.2.7 Competition colonisation study .....	193
<b>6.3 Mutational Analysis of Individual Components of the Genomic Island .....</b>	<b>199</b>
6.3.1 Construction of mutants of strains WCH206 and MSHR5 .....	199
6.3.2 Growth curve .....	201

6.3.3 Pneumonia/sepsis competition study	203
6.3.4 RNA analysis of WCH206 $\Delta$ ROK	209
<b>6.4 Discussion</b>	<b>212</b>

---

## **Chapter 7: Whole Genome Analysis of Unrelated Serotype 3 Strains**

---

<b>7.1 Introduction</b>	<b>217</b>
<b>7.2 <i>In silico</i> Analysis of the OXC141 Genome</b>	<b>218</b>
<b>7.3 Second Generation Sequencing</b>	<b>221</b>
7.3.1 PCR and sequence analysis of selected gaps	238
7.3.2.1 Gap 1 of WU2	238
7.3.2.2 Gap 1 of MSHR17	239
7.3.2.3 Gap 2 of MSHR17 and WU2	239
7.3.2.4 Gap 3 of MSHR17 and WU2	241
7.3.2.5 Gap 4 of MSHR17	242
7.3.2.6 Gap 5 of MSHR17	244
7.3.2.7 Gap 6 of MSHR17/Gap 4 of WU2	246
7.3.2.8 Gap 5 of WU2	248
7.3.3 Assembly and analysis of the “boneyards” sequences	248
7.3.3.1 Accessory region 1 of MSHR17	256
7.3.3.2 Accessory region 1 of WU2	257
7.3.3.3 Accessory region 2 of WU2	257
7.3.3.4 Accessory region 3 of WU2	261
7.3.3.5 Accessory region 4 of WU2	261

---

7.3.3.6 Accessory region 5 of WU2.....	261
7.3.3.7 Accessory region 6 of WU2.....	263
7.3.3.8 Accessory region 7 of WU2.....	263
7.3.3.9 PCR analysis of the accessory region 1 of MSHR17.....	265
<b>7.4 Reconciliation of Genome Sequencing Data with Chapter 4 Data.....</b>	<b>265</b>
7.4.1 Comparison to microarray data.....	265
7.4.2 Comparison to PCR-based subtractive hybridisation data.....	268
<b>7.5 Discussion.....</b>	<b>269</b>

---

<b>Chapter 8: Final Discussion</b>	
------------------------------------	--

---

<b>8.1 Introduction.....</b>	<b>275</b>
8.1.1 Characetrisation of clinical isolates from Aboriginal communities.....	276
8.1.2 Serotype, genetic background and disease.....	278
8.1.3 Genomic analysis of serotype 3 isolates.....	280
8.1.4 Distribution and mutational analysis of the island.....	281
8.1.5 Accessory regions and otitis media.....	283
8.1.6 Summary and conclusion.....	285
<b>8.2 Future Directions.....</b>	<b>286</b>

  

<b>Appendix.....</b>	<b>289</b>
<b>Bibliography.....</b>	<b>306</b>

---

## Abstract

---

*Streptococcus pneumoniae* is the principal bacterial cause of otitis media (OM). While OM does not have the high rates of mortality associated with invasive pneumococcal diseases, such as meningitis, it has an extremely high rate of morbidity, with most children suffering at least one episode of OM during their early childhood years. Despite being a major public health burden worldwide, certain communities are more impacted than others. In Australia, remote Aboriginal communities have the highest rates of OM in the world with absolutely no improvement over the last few decades. Therefore, understanding the pathogenesis of pneumococcal OM is of vital importance.

At the start of this project, serotype 3 middle ear and nasopharyngeal isolates were obtained from both remote Aboriginal communities and the general Australian population from the Menzies School of Health Research (MSHR) in Darwin and the Women's and Children's Hospital (WCH) in Adelaide, respectively. This serotype is an important middle ear pathogen, including in remote Aboriginal communities. In addition, serogroup 11 nasopharyngeal and sinusitis isolates were received from the same sources. Serogroup 11 is rarely reported in OM in remote Australian Aboriginal communities and is generally not as prevalent as serotype 3 in other communities. Furthermore, the serogroup 11 isolates tested were avirulent in mouse invasive disease models, while the serotype 3 isolates tested were virulent.

A serotype 11A nasopharyngeal isolate from a remote Aboriginal community was capsule switched to serotype 3. However, in a pneumonia/sepsis mouse model, it was less fit in the middle ears compared to the middle ear isolate from which the serotype 3 capsule

locus was derived. This indicated the serotype 3 isolates of this study possess genetic factors apart from serotype that influence OM.

Multilocus sequence typing identified two STs in the serotype 3 middle ear isolates (ST180 and ST458). Generally, ST180 is the dominant ST within serotype 3 worldwide, but interestingly, all the isolates typed from MSHR belonged to ST458. The genomes of ST180 and ST458 isolates were analysed using a variety of molecular biological techniques, including a comparison with serogroup 11 isolates by DNA microarray analysis. However, no gene common to one serotype/group but not the other was identified and therefore, the capsule loci remained the only distinguishing feature between serotype 3 and serogroup 11. In order to determine if there were any genes present in the genomes of ST180 and ST458 isolates which were not represented on the microarray slide, PCR-based subtractive hybridisation was employed, and a putative cellobiose phosphotransferase system (PTS) was identified. This PTS is part of a 10 kb island, which includes a sulfatase and ROK family protein. However, there is a large deletion in ST458, which includes the sulfatase and part of the putative cellobiose PTS operon. A large number of strains from a variety of serotype/groups, which included serogroup 11, were found to carry the island through PCR analysis or bioinformatic searches, with most possessing the full island. In ST180, mutagenesis of the island and subsequent virulence studies revealed that the island confers a competitive advantage in a variety of niches, including the ear. Unfortunately, mutagenesis in ST458 was not possible despite numerous attempts.

Finally, the availability of next generation sequencing and a fully sequenced genome of a serotype 3 ST180 strain (OXC141), allowed the investigation for genes which had been missed by PCR-based subtractive hybridisation due to limitations with this technique. The genome of an ST458 middle ear isolate (MSHR17) was analysed, along with an unrelated serotype 3 strain (WU2) as a comparison. Both OXC141 and MSHR17

had regions not represented on the microarray slide, but these regions had not been detected by PCR-based subtractive hybridisation due to their absence in the other ST. Therefore, the PTS island remained the only region common to both STs. Nonetheless, the repertoire of regions possessed by ST180 may explain the dominance of this ST in serotype 3 worldwide, while the repertoire possessed by ST458 may mean it is better adapted to the microenvironmental niches encountered in remote Aboriginal communities.

---

## Declaration

---

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Lauren Joy McAllister, and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

.....

Lauren Joy McAllister

.../.../.....

## Acknowledgements

---

I really could not have completed my PhD without the support of many others, and it is difficult to find the words to express the extent of my gratitude to the people below.

First of all, thank you to Professor James Paton for being willing to show me around the lab and introduce me to his work all those years ago when I approached him as a Science Scholars student. You have really fostered a love for microbiology in me, and I appreciate the belief you have shown in me and the opportunity to have done a summer scholarship, Honours and PhD with you. I would also like to thank my other two supervisors, Dr Uwe Stroehler and Dr David Ogunniyi, for their tremendous support and encouragement and for always being available, except Thursday lunchtimes! Special thanks to Uwe for helping me with the tedious task of making files for all the poor alignments and gaps in the second generation sequencing data, and Dave for checking on the mice in the middle of the night for me. A huge thanks to the former lab manager Jan Cook for keeping the lab in order and for always willing to help sort out any issues I may have had, as well as all the help you gave me for my mouse work. Thanks to Dr Tony Focareta for always taking an interest in what I was doing (as well as my family). With comments such as “Did the hairdresser make a mistake with your hair dye?”, at least you have ensured I will not leave my PhD with a big ego. Thanks also to Dr Kerrie Grabowski



for always being over-the-top considerate in the lab, especially worrying about distracting me or making too much noise while I wrote.

To Richard Harvey, thanks for your great company throughout my PhD and always lending an ear when I have wanted someone to talk about my project with. Also, for the timeless advice of not eating M<sup>c</sup>Donald's before running. Thanks to everyone else I have shared an office with throughout my PhD no matter how long or short: Dr Kim LeMessurier, James Byrne, Charlie Plumptre, Brock Herdman, Daphne Mermans and Nadine Verhoeven. I have enjoyed everyone's company, as well as thankful for you putting up with my mess. I would like to thank the other members of the Paton lab both past and present: Dr Austin Chen, Dr Damien Chong, Xiao Hui Gao, Dr Sylvia Herold, Dr Layla Mahdi, Dr Judy Morona, Dr Adrienne Paton, Stephanie Philp, Dr Adam Potter, Dr Trish Rogers, Dr Alistair Standish, Ursula Talbot, Dr Claudia Trappetti, Dr Hui Wang, as well as Dr Chris McDevitt. There are too many people to acknowledge individually, but you have all helped make my PhD an enjoyable and rewarding experience. Thanks to everyone from the Morona lab for their friendliness and who like all good neighbours are always willing to lend something when needed. Thanks also to the CSU, LAS, and Molecular Pathology Unit of the IMVS, as well as Geneworks, for their services.

A huge thanks to my family, especially Mum, for always being there for me. I couldn't ask for a more supportive family. Thanks also to my friends, especially the girls at Craft Saturday for giving me the chance to think about something other than my thesis, Sophia Tan for organising lots of trips to Chocolate Bean, and Keiko, whose huge work ethic and fighting spirit inspires me when I am having a bad day. Also, to my former sharemate Anna and current sharemate Jenny for not only being willing to share a house with someone doing a PhD, but always being there to share good and bad days with.

Special thanks to Jenny for all her support, understanding and encouragement while I finished writing up.

Finally, I would like to thank Dr Amanda Leach from the Menzies School of Health Research in Darwin and Andrew Lawrence from the Women's and Children's Hospital in Adelaide for providing strains used in this study, as well as acknowledge the Australian indigenous communities who allowed the use of the bacterial isolates from the Menzies School of Health Research in this study.

---

## List of Abbreviations

---

This thesis uses abbreviations that are acceptable to the American Society for Microbiology without definition. Listed below are additional abbreviations, which are defined when first used in the text.

A <sub>520,540,570,600</sub>	Absorbance at 520, 540, 570, 600 nm, respectively
Amp	Ampicillin
AOM	Acute otitis media
AP	Alkaline phosphatase
AR	Accessory region
BA	Blood agar
BHI	Brain heart infusion
bp	Base pair(s)
BSA	Bovine serum albumin
CBP	Choline binding protein
CFU	Colony forming unit
CSOM	Chronic suppurative otitis media
CPS	Capsule
CSP	Competence stimulating peptide
C-terminus	Carboxy terminus
DIG	Digoxigenin
DOC	Sodium deoxycholate
EDTA	Ethylene diamine tetraacetic acid
Ery	Erythromycin
<i>g</i>	Gravity units
GAG	Glycoaminoglycan
Gent	Gentamycin
h	Hours

Hic	Factor H-binding inhibitor of complement
hRBC	Human red blood cells
IgA	Immunoglobulin A
i.n.	Intranasal
i.p.	Intraperitoneal
IPD	Invasive pneumococcal disease
JCVI	J. Craig Venter Institute, San Diego and Rockville, USA
kb	Kilobase pair (s)
KEGG	Kyoto Encyclopedia of Genes and Genomes
LB	Luria Bertani broth
LD <sub>50</sub>	50% lethal dose
LPS	Lipopolysaccharide
LPxTG	Leucine-proline-x-threonine-glycine binding motif
LytA	Autolysin A
min	Minute(s)
MLST	Multilocus sequence type
MSHR	Menzies School of Health Research, Darwin, Australia
Nan(A,B,C)	Neuraminidase (A, B, C)
NCBI	National Center for Biotechnology Information at the U.S. National Library of Medicine, Bethesda, Maryland, USA
nt	Nucleotide(s)
N-terminus	Amino terminus
OM	Otitis media
OME	Otitis media with effusion
O/N	Overnight
ORF	Open reading frame
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
Ply	Pneumolysin
PP1	Pneumococcal pathogenicity island 1
PspA	Pneumococcal surface protein A
PspC	Pneumococcal surface protein C
PTS	Phosphotransferase system
PTS 1	The putative cellobiose PTS identified in Chapter 4 of this study

---

PTS 2	The putative cellobiose PTS described by McKessar and Hakenbeck (2007)
RD	Region of diversity
ROK	Repressor, ORF of unknown function, kinase
RT	Room temperature
RT-PCR	Reverse transcriptase polymerase chain reaction
SB	Serum broth
SDS	Sodium dodecyl sulphate
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
Sec	Second (s)
ST	Sequence type
TEMED	N,N,N',N'-tetramethyl-ethylene-diamine
TH	Todd-Hewitt broth
THY	Todd-Hewitt broth supplemented with yeast extract
WCH	Women's and Children's Hospital, Adelaide, Australia
WHO	World Health Organization
X-gal	5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside